Holen Sie sich die Stockscreener-App
2.58
7.05%
0.17
Handel nachbörslich:
2.57
-0.01
-0.39%
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Neuraxis announces new medical policy with two health insurers - TipRanks
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives - GlobeNewswire
NeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal Pain - Nasdaq
NeurAxis (NASDAQ:NRXS) Now Covered by Analysts at Craig Hallum - Defense World
Neuraxis (NRXS) Initiated with Buy Rating by Craig-Hallum | NRXS Stock News - GuruFocus
Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device - Investing.com India
Craig-Hallum bullish on Neuraxis, initiates with a Buy - TipRanks
Neuraxis, Inc. Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain in Ibs - MarketScreener
NeurAxis (NRXS) Gains Momentum with Key Guideline Inclusion | NR - GuruFocus
Neuraxis secures key academic society guidelines recommendation for FAP - TipRanks
NeurAxis Achieves Critical Milestone; Secures Key Academic - GlobeNewswire
Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option - Stock Titan
47,094 Shares in NeurAxis, Inc. (NASDAQ:NRXS) Bought by Citadel Advisors LLC - Defense World
NeurAxis, Inc. Approves Key Proposals at Annual Meeting - TipRanks
NeurAxis, Inc. Releases Investor Presentation - TipRanks
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times
Biotech Alert: Searches spiking for these stocks today - TipRanks
NeurAxis Closes $5 Million Direct Offering - marketscreener.com
NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire
NeurAxis announces USD 5M registered direct offering - Medical Buyer
NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks
Form 424B5 Neuraxis, INC - StreetInsider
SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow
Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa
NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks
Neuraxis settles lawsuit with $750,000 agreement - Investing.com
NeurAxis slides 21%, raises $5M via stock - MSN
Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize
NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq
NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus
NeurAxis Launches $5 Million Direct Offering - marketscreener.com
NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus
Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks
NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com
NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com
NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph
Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga
NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com
NeurAxis, Inc. Receives First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia and Associated Nausea Symptoms - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus
0.68%
0.50%
Kapitalisierung:
|
Volumen (24h):